Published in BMC Cancer on November 15, 2012
Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas. J Clin Pathol (2014) 0.91
Coexpression of EpCAM, CD44 variant isoforms and claudin-7 in anaplastic thyroid carcinoma. PLoS One (2014) 0.87
A papillary thyroid microcarcinoma revealed by a single bone lesion with no poor prognostic factors. Case Rep Endocrinol (2013) 0.79
Using aptamers to elucidate esophageal cancer clinical samples. Sci Rep (2015) 0.78
Protein mislocalization: mechanisms, functions and clinical applications in cancer. Biochim Biophys Acta (2014) 0.76
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA (2006) 22.71
Thyroid carcinoma. Lancet (2003) 4.08
Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer (1985) 3.69
The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res (2009) 3.25
Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer (2003) 2.58
EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis (2010) 2.13
Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer (2010) 1.96
Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg (2010) 1.86
The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid (2011) 1.85
The epidemiology of thyroid disease and implications for screening. Endocrinol Metab Clin North Am (1997) 1.75
Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol (2008) 1.65
Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J Clin Endocrinol Metab (2012) 1.46
Recurrence after treatment of micropapillary thyroid cancer. Thyroid (2009) 1.41
A therapeutic strategy for incidentally detected papillary microcarcinoma of the thyroid. Nat Clin Pract Endocrinol Metab (2007) 1.35
Papillary microcarcinoma of the thyroid: how should it be treated? World J Surg (2004) 1.26
EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis. BMC Cancer (2010) 1.17
New subgrouping of small thyroid carcinomas. Cancer (1987) 1.03
Nuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers. PLoS One (2010) 1.00
Treatment for microcarcinoma of the thyroid--clinical experience. Clin Nucl Med (2007) 1.00
Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid (2007) 0.98
Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma. Eur J Endocrinol (2012) 0.97
Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab (2002) 0.96
Papillary thyroid microcarcinomas: big decisions for a small tumor. Ann Surg Oncol (2009) 0.95
S100A4 expression is associated with lymph node metastasis in papillary microcarcinoma of the thyroid. Mod Pathol (2008) 0.93
Approach to the patient with incidental papillary microcarcinoma. J Clin Endocrinol Metab (2010) 0.92
Comparative analysis of gene expression profiles of papillary thyroid microcarcinoma and papillary thyroid carcinoma. J Cancer Res Ther (2011) 0.90
An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma. PLoS One (2012) 0.88
Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer? Front Endocrinol (Lausanne) (2012) 0.84
Brain metastases with exceptional features from papillary thyroid carcinoma: report of three cases. Hell J Nucl Med (2011) 0.84
Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. Head Neck (2010) 2.29
Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab (2003) 1.98
Identification of differentially expressed genes in oral squamous cell carcinoma. Mol Carcinog (2005) 1.36
Randomized comparison of the effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the wellbeing of patients. Nutr J (2004) 1.35
Claudin 1 overexpression increases invasion and is associated with aggressive histological features in oral squamous cell carcinoma. Cancer (2008) 1.35
Expression analysis of E-cadherin, Slug and GSK3beta in invasive ductal carcinoma of breast. BMC Cancer (2009) 1.29
Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci (2007) 1.20
Mechanisms of action of the congenital diaphragmatic hernia-inducing teratogen nitrofen. Am J Physiol Lung Cell Mol Physiol (2007) 1.19
Curcumin down regulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cells. Toxicology (2006) 1.18
Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci (2007) 1.17
EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis. BMC Cancer (2010) 1.17
Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol (2009) 1.16
Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res (2008) 1.14
Over-expression of 14-3-3zeta is an early event in oral cancer. BMC Cancer (2007) 1.09
Thyroid hormone response element organization dictates the composition of active receptor. J Biol Chem (2007) 1.07
MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma. Oncology (2005) 1.07
Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer. Breast Cancer Res Treat (2006) 1.06
Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between beta-catenin, dishevelled and cyclin D1 expression. Oncology (2008) 1.06
Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and -independent pathways. Am J Pathol (2002) 1.05
Nuclear S100A7 is associated with poor prognosis in head and neck cancer. PLoS One (2010) 1.04
Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sci (2010) 1.04
Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma. Int J Cancer (2009) 1.03
Epigenetic alterations of CDH1 and APC genes: relationship with activation of Wnt/beta-catenin pathway in invasive ductal carcinoma of breast. Life Sci (2008) 1.03
Clinical significance of altered expression of β-catenin and E-cadherin in oral dysplasia and cancer: potential link with ALCAM expression. PLoS One (2013) 1.02
Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma. Head Neck (2009) 1.02
Angiogenesis in cutaneous melanoma: pathogenesis and clinical implications. Microsc Res Tech (2003) 1.02
Stromelysin 3, Ets-1, and vascular endothelial growth factor expression in oral precancerous and cancerous lesions: correlation with microvessel density, progression, and prognosis. Clin Cancer Res (2005) 1.01
Expression of DNA methyltransferases in breast cancer patients and to analyze the effect of natural compounds on DNA methyltransferases and associated proteins. J Breast Cancer (2013) 1.01
Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography-tandem mass spectrometry. J Proteome Res (2008) 1.00
Prognostic variables and calcitonin in medullary thyroid cancer. Laryngoscope (2005) 1.00
Nuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers. PLoS One (2010) 1.00
Stromelysin-2 overexpression in human esophageal squamous cell carcinoma: potential clinical implications. Cancer Detect Prev (2002) 0.99
Prognostic factors in well-differentiated thyroid carcinoma. Laryngoscope (2004) 0.99
Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/beta-catenin signaling. Chem Biol Interact (2009) 0.99
S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia. Int J Cancer (2013) 0.99
Detection of RASSF1A and RARbeta hypermethylation in serum DNA from breast cancer patients. Epigenetics (2006) 0.97
14-3-3 zeta as novel molecular target for cancer therapy. Expert Opin Ther Targets (2012) 0.96
Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients. Cell Oncol (2009) 0.96
Stromelysin-3 expression is an early event in human oral tumorigenesis. Int J Cancer (2003) 0.95
Clinical course of thyroid carcinoma after neck dissection. Laryngoscope (2003) 0.95
Molecular classification of oral cancer by cDNA microarrays identifies overexpressed genes correlated with nodal metastasis. Int J Cancer (2004) 0.95
Small interfering RNA targeting 14-3-3ζ increases efficacy of chemotherapeutic agents in head and neck cancer cells. Mol Cancer Ther (2010) 0.94
Alterations of rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma. Oncology (2005) 0.94
CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clin Biochem (2009) 0.94
Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab (2015) 0.94
Ets-1 and VEGF expression correlates with tumor angiogenesis, lymph node metastasis, and patient survival in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol (2003) 0.93
Expression of NF-kappaB parallels COX-2 expression in oral precancer and cancer: association with smokeless tobacco. Int J Cancer (2007) 0.93
Thyroid cancer outcomes in Filipino patients. Arch Otolaryngol Head Neck Surg (2010) 0.92
Differential expression of G-protein coupled receptor 56 in human esophageal squamous cell carcinoma. Cancer Lett (2006) 0.92
Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients. Int J Cancer (2009) 0.92
Cellular context of coregulator and adaptor proteins regulates human adenovirus 5 early region 1A-dependent gene activation by the thyroid hormone receptor. Mol Endocrinol (2003) 0.92
Promoter hypermethylation in Indian primary oral squamous cell carcinoma. Int J Cancer (2010) 0.92
Prognostic significance of nuclear pSTAT3 in oral cancer. Head Neck (2011) 0.91
The adenovirus E1A protein targets the SAGA but not the ADA transcriptional regulatory complex through multiple independent domains. J Biol Chem (2002) 0.91
Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression. Tumour Biol (2010) 0.91
Extrathyroidal extension in well-differentiated thyroid cancer: macroscopic vs microscopic as a predictor of outcome. Arch Otolaryngol Head Neck Surg (2007) 0.91
Discovery of deregulation of zinc homeostasis and its associated genes in esophageal squamous cell carcinoma using cDNA microarray. Int J Cancer (2007) 0.90
Transglutaminase 2 overexpression in tumor stroma identifies invasive ductal carcinomas of breast at high risk of recurrence. PLoS One (2013) 0.90
Predictive value of serum thyroglobulin after surgery for thyroid carcinoma. Laryngoscope (2003) 0.89
Overexpression of prothymosin alpha predicts poor disease outcome in head and neck cancer. PLoS One (2011) 0.89
Transient neonatal hypothyroidism is associated with elevated serum anti-thyroglobulin antibody levels in newborns and their mothers. J Pediatr (2007) 0.89
E1A and a nuclear receptor corepressor splice variant (N-CoRI) are thyroid hormone receptor coactivators that bind in the corepressor mode. Proc Natl Acad Sci U S A (2005) 0.89
Clinical significance of GPR56, transglutaminase 2, and NF-κB in esophageal squamous cell carcinoma. Cancer Invest (2010) 0.89
Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents. Mol Cell Biochem (2010) 0.89
DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients. Tumour Biol (2012) 0.88
14-3-3 zeta is a molecular target in guggulsterone induced apoptosis in head and neck cancer cells. BMC Cancer (2010) 0.88
An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma. PLoS One (2012) 0.88
TC21/R-Ras2 upregulation in esophageal tumorigenesis: potential diagnostic implications. Oncology (2005) 0.87
Clinical significance of TC21 overexpression in oral cancer. J Oral Pathol Med (2009) 0.87
Significance of promoter hypermethylation of p16 gene for margin assessment in carcinoma tongue. Head Neck (2009) 0.86
Guggulsterone (GS) inhibits smokeless tobacco and nicotine-induced NF-κB and STAT3 pathways in head and neck cancer cells. Carcinogenesis (2010) 0.86
Three-week thyroxine withdrawal: a thyroid-specific quality of life study. Laryngoscope (2006) 0.86
Clinical significance of sperm protein 17 expression and immunogenicity in esophageal cancer. Int J Cancer (2007) 0.86
Establishment and characterization of a cell line from smokeless tobacco associated oral squamous cell carcinoma. Oral Oncol (2003) 0.85
Secretome-based identification and characterization of potential biomarkers in thyroid cancer. J Proteome Res (2010) 0.85
Iodine nutrition during pregnancy in Toronto, Canada. Endocr Pract (2013) 0.85
Clinical significance of Stratifin, ERalpha and PR promoter methylation in tumor and serum DNA in Indian breast cancer patients. Clin Biochem (2009) 0.84
MGMT expression in oral precancerous and cancerous lesions: correlation with progression, nodal metastasis and poor prognosis. Oral Oncol (2006) 0.84
Clinical significance of promoter hypermethylation of ERβ and RARβ2 in tumor and serum DNA in Indian breast cancer patients. Ann Surg Oncol (2012) 0.84
Differential expression of retinoic acid receptors in normal and malignant esophageal tissues. J Exp Ther Oncol (2004) 0.83
Transcriptional gene expression profile of human esophageal squamous cell carcinoma. Genomics (2003) 0.83
Smokeless tobacco (khaini) extracts modulate gene expression in epithelial cell culture from an oral hyperplasia. Oral Oncol (2005) 0.83
Novel molecular targets of smokeless tobacco (khaini) in cell culture from oral hyperplasia. Toxicology (2006) 0.82
Expression analysis of maspin in invasive ductal carcinoma of breast and modulation of its expression by curcumin in breast cancer cell lines. Chem Biol Interact (2009) 0.82
Sperm protein 17 is a novel marker for predicting cisplatin response in esophageal squamous cancer cell lines. Int J Cancer (2010) 0.81
The adenoviral E1A protein displaces corepressors and relieves gene repression by unliganded thyroid hormone receptors in vivo. Cell Res (2009) 0.81
Predictive value of metastatic cervical lymph node ratio in papillary thyroid carcinoma recurrence. Head Neck (2012) 0.81
Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma. Head Neck (2008) 0.81
A sensitive test for the detection of specific DSB repair defects in primary cells from breast cancer specimens. Int J Cancer (2008) 0.81